NCT00859495 · ADVERSE EVENTS

Adverse events

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma · Source last updated 2020-08-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 20 weeks
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Multimodal Lung Sparing Regimen Intrapleural chemotherapy plus systemic chemotherapy: Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy. Doxorubicin: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species. Cisplatin: Platinum-based antineoplastic Pemetrexed: Folate Analog Metabolic Inhibitor Radiotherapy: Standard procedure given 3 weeks after last dose of chemotherapy	0 / 9	0 / 9	0 / 9

Group identifiers: EG000: Multimodal Lung Sparing Regimen

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

deaths Num Affected
0
deaths Num At Risk
9
description
Intrapleural chemotherapy plus systemic chemotherapy: Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy. Doxorubicin: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species. Cisplatin: Platinum-based antineoplastic Pemetrexed: Folate Analog Metabolic Inhibitor Radiotherapy: Standard procedure given 3 weeks after last dose of chemotherapy
id
EG000
other Num Affected
0
other Num At Risk
9
serious Num Affected
0
serious Num At Risk
9
title
Multimodal Lung Sparing Regimen

frequency Threshold

time Frame

20 weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice